Teleflex (TFX)
(Delayed Data from NYSE)
$201.92 USD
-1.58 (-0.78%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.74 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.92 USD
-1.58 (-0.78%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.74 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes
by Zacks Equity Research
Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.
Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses
by Zacks Equity Research
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.
Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.
Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 15.84% and 0.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
by Zacks Equity Research
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Teleflex (TFX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 17.13% and 4.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Moves 3.8% Higher: Will This Strength Last?
by Zacks Equity Research
Teleflex (TFX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
by Zacks Equity Research
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
by Zacks Equity Research
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark
by Zacks Equity Research
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates
by Zacks Equity Research
Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.
Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow
by Zacks Equity Research
Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.
Masimo (MASI) Reports Study Findings Backing the SedLine
by Zacks Equity Research
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.